Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...
The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...
This type of brain tumor can range from slow-growing to highly aggressive forms. Learn how astrocytomas are diagnosed and treated and what factors influence a person’s outlook and recovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback